Last reviewed · How we verify

Azilsartan medoxomil and hydrochlorothiazide

Takeda · Phase 3 active Small molecule

Azilsartan medoxomil and hydrochlorothiazide is a Angiotensin II receptor blocker (ARB) + thiazide diuretic combination Small molecule drug developed by Takeda. It is currently in Phase 3 development for Hypertension (high blood pressure). Also known as: TAK-491, TAK-491CLD.

Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume.

Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume. Used for Hypertension (high blood pressure).

At a glance

Generic nameAzilsartan medoxomil and hydrochlorothiazide
Also known asTAK-491, TAK-491CLD
SponsorTakeda
Drug classAngiotensin II receptor blocker (ARB) + thiazide diuretic combination
TargetAT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing blood volume and electrolyte levels. The combination provides complementary antihypertensive effects through different mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Azilsartan medoxomil and hydrochlorothiazide

What is Azilsartan medoxomil and hydrochlorothiazide?

Azilsartan medoxomil and hydrochlorothiazide is a Angiotensin II receptor blocker (ARB) + thiazide diuretic combination drug developed by Takeda, indicated for Hypertension (high blood pressure).

How does Azilsartan medoxomil and hydrochlorothiazide work?

Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume.

What is Azilsartan medoxomil and hydrochlorothiazide used for?

Azilsartan medoxomil and hydrochlorothiazide is indicated for Hypertension (high blood pressure).

Who makes Azilsartan medoxomil and hydrochlorothiazide?

Azilsartan medoxomil and hydrochlorothiazide is developed by Takeda (see full Takeda pipeline at /company/takeda).

Is Azilsartan medoxomil and hydrochlorothiazide also known as anything else?

Azilsartan medoxomil and hydrochlorothiazide is also known as TAK-491, TAK-491CLD.

What drug class is Azilsartan medoxomil and hydrochlorothiazide in?

Azilsartan medoxomil and hydrochlorothiazide belongs to the Angiotensin II receptor blocker (ARB) + thiazide diuretic combination class. See all Angiotensin II receptor blocker (ARB) + thiazide diuretic combination drugs at /class/angiotensin-ii-receptor-blocker-arb-thiazide-diuretic-combination.

What development phase is Azilsartan medoxomil and hydrochlorothiazide in?

Azilsartan medoxomil and hydrochlorothiazide is in Phase 3.

What are the side effects of Azilsartan medoxomil and hydrochlorothiazide?

Common side effects of Azilsartan medoxomil and hydrochlorothiazide include Dizziness, Fatigue, Hyperkalemia (elevated potassium), Hypokalemia (low potassium), Hyperuricemia (elevated uric acid), Headache.

What does Azilsartan medoxomil and hydrochlorothiazide target?

Azilsartan medoxomil and hydrochlorothiazide targets AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter and is a Angiotensin II receptor blocker (ARB) + thiazide diuretic combination.

Related